New research indicates that curcumin--a substance in turmeric that is best known as one of the main components of curry powder--may help fight drug-resistant tuberculosis. In Asia, turmeric is used to treat many health conditions and it has anti-inflammatory, antioxidant, and perhaps even anticancer properties.
Investigators found that by stimulating human immune cells called macrophages, curcumin was able to successfully remove Mycobacterium tuberculosis, the causative bacterium of tuberculosis, from experimentally infected cells in culture. The process relied on inhibiting the activation of a cellular molecule called nuclear factor-kappa B.
The ability of curcumin to modulate the immune response to Mycobacterium tuberculosis points to a potential new tuberculosis treatment that would be less prone to the development of drug resistance.
"Our study has provided basic evidence that curcumin protects against Mycobacterium tuberculosis infection in human cells," said Dr. Xiyuan Bai, lead author of the Respirology study. "The protective role of curcumin to fight drug-resistant tuberculosis still needs confirmation, but if validated, curcumin may become a novel treatment to modulate the host immune response to overcome drug-resistant tuberculosis."
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.